Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Key Steps to Help Individuals Overcome Alcohol Addiction

Key Steps to Help Individuals Overcome Alcohol Addiction

If a patient is ready to accept help with their alcohol problem it’s the first step in an important and long journey. A willing and strong 3rd party can be the much needed first step of support that helps someone get back to sober living in Dallas, or wherever you are located. Professional help always starts with a detox program and is the best way forward.

During detox, a person’s dependence on alcohol can be managed with medications, so that the person’s withdrawal symptoms are minimized. Medications can also help to reduce the risk of seizures, which can occur in the most severe cases of withdrawal.

Detox can take place in a hospital, or in a residential rehab facility. Once detox is complete, the individual can then go to an inpatient or outpatient rehab facility to complete the alcohol addiction treatment process.

Inpatient of Outpatient Rehab?

Inpatient rehab is best for people who need medical monitoring for detox and who need intensive therapy at the beginning of the recovery process. Inpatient care provides close 24-hour supervision by trained and licensed staff. The rehab staff monitors progress and provides support and motivation to encourage the person to complete the program.

Outpatient rehab allows patients to rest at home while attending therapy sessions at a clinic or treatment facility. The availability of therapy for those who are working is an important consideration for many people. Outpatient rehab works for those who are able to sustain a commitment to recovery in their daily lives without requiring close supervision.

Of course, the more severe the addiction, the more intensive the treatment needs to be. Inpatient rehab offers the most intensive care, as it is designed for people who need to focus on the addiction entirely. Outpatient care is more suitable for people who are able to balance their addiction treatment with their professional and personal lives.

What to expect after treatment?

Once alcohol has been removed from the body, the patient can begin to adjust to living without it. This is a process that is likely to take a long time. It may be more difficult for people who have been addicted to alcohol for a long time.

The patient may experience cravings for alcohol as they adjust to sobriety. In order to reduce the odds of returning to drinking, the patient must learn the skills needed to avoid and deal with the triggers that lead them to drink.

What about relapse?

Some of the most common behaviors that lead to relapse include spending time with people who drink, going to bars or parties where alcohol is served and having alcohol in the home. In order to avoid these triggers, the patient can participate in activities that are not likely to expose them to situations where they are likely to drink. These may include attending self-help meetings, getting a job that requires a lot of time away from home and spending time with supportive people who have not been drinking.

Final thoughts

It is important to remember that alcohol addiction is not a sign of weakness, but rather a disease that causes people to behave in ways that are harmful to themselves and others. For this reason, many doctors do not recommend that people with this disease be punished, but rather that they be given the opportunity to get the help that they need. Remember this when trying to help your loved one back to sobriety.

Abbott Receives CE Mark Approval for Next-Generation TriClip Device, Offering New Innovations for Tricuspid Heart Valve Repair

dd

Abbott announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient’s unique anatomy.

Often referred to as the “forgotten valve” because of historically limited treatment options, the tricuspid valve has three leaflets that control the flow of blood between the two chambers on the right side of the heart (right ventricle and right atrium). When those leaflets do not close properly, blood can flow in the reverse direction – known as regurgitation – forcing the heart to work harder. The condition typically impacts older individuals who have multiple co-morbidities, making open-heart surgery a high-risk procedure and resulting in many people going untreated. When left unaddressed, TR can lead to debilitating conditions such as atrial fibrillation (AF), heart failure and, ultimately, death.1

“Since its initial CE Mark in April 2020, TriClip has emerged as a much-needed treatment option, offering physicians the opportunity to dramatically improve the quality of life for people in Europe with severe, symptomatic tricuspid regurgitation who are not responding to medical therapy and are often so ill they cannot undergo surgery,” said Philipp Lurz, M.D., Ph.D., professor and deputy head of cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany. “This newest generation device further improves cardiologists’ ability to safely and effectively repair the tricuspid valve, which historically has been extremely challenging to treat.”

Leveraging Abbott’s technology and robust body of evidence from the company’s leading MitraClip™ device – the safe, effective and minimally invasive option to repair leaky mitral valves (or mitral regurgitation) – TriClip was specifically designed to treat the tricuspid valve’s complex anatomy. With a precise and stable delivery system engineered for navigating the right side of the heart, TriClip offers physicians new options for treating debilitating TR.

Recent data for TriClip from the TRILUMINATE CE Mark study showed sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status, demonstrating the benefits of the therapy and ultimately proving TriClip as a safe and durable treatment option for high-risk patients with symptomatic moderate or greater TR.

TriClip is delivered to the heart via a catheter inserted through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. With its differentiated delivery system designed specifically for the tricuspid valve and a steerable guiding catheter system, physicians can independently grasp and effectively clip leaflets of the tricuspid valve to reduce the regurgitation. This latest innovation includes two new clip sizes, offering clinicians a total of four sizes to tailor the device to different patient anatomies.

“Tricuspid regurgitation is considered the most undertreated valve issue and our newest generation device to address it is the result of our unwavering commitment to restore health and improve the quality of life for patients with structural heart disease,” said Mike Dale, senior vice president of Abbott’s structural heart business. “Our novel TriClip therapy offers the best possible outcomes for people suffering from a debilitating condition and gives doctors even more options for customizing repair of this complex anatomy.”

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Servier together with World Heart Federation and Global Heart Hub, launches “Use Heart to Act Now on Angina,” a public campaign to raise awareness on angina

Servier

Servier, an international pharmaceutical group, with World Heart Federation (WHF), the principal representative body for the global cardiovascular (CV) community, and Global Heart Hub (GHH), the principal association for patients with CV disease, will launch “Use Heart to Act Now on Angina” on April 20. This worldwide campaign aims to raise public awareness about the symptoms of angina, which are often underestimated. The official launch of the campaign will take place during a webinar run by WHF President, Prof. Fausto Pinto, on April 20 at 14:00 CEST. The webinar will leverage learnings from the prolonged Covid-19 pandemic, emphasizing that now, more than ever, it is necessary to continue to focus on heart health and that consulting your doctor promptly is key to positive health outcomes.

Angina affects more than 100 million people globally

Angina is a manifestation of chronic coronary syndrome (CCS) which includes an imbalance in the demand and supply of oxygen in the heart muscle. CCS itself is a multifactorial disease, meaning that

angina can be triggered by different mechanisms, such as the obstruction of coronary arteries with plaques through coronary artery disease (CAD), microvascular disease, and spasms.

More than 100 million people globally are affected and the huge impact of angina on the quality of life of patients includes consequences such as disability, job loss, and depression. As angina manifests in a variety of ways, the symptoms may be hard to recognize, and risk being attributed to stress, menopause, or digestive issues.

The incidence and prevalence of patients with angina is expected to increase in the coming decade as a result of an aging population, the obesity epidemic, the greater use of life-prolonging therapies, and better management of acute coronary syndromes.

“Use Heart to Act Now on Angina” is a worldwide campaign to improve disease awareness, facilitate timely detection of angina patients, and implement optimal angina management. 

Angina patients often remain underdiagnosed and undertreated. It is essential for early warning signs to be recognized in time by both health professionals and patients alike.

Therefore Servier, the World Heart Federation, and WHF’s Member organization, the Global Heart Hub are forging a path in the fight to address the urgency of angina symptoms, its potential consequences, and necessary care. “Use Heart to Act Now on Angina” is a new joint initiative that brings together the latest medical perspectives and patient views in order to ensure that we take angina seriously.

Elsa Steo, WomenHeart Ambassador 2021, stated: “I was really lucky. I saw a new, young doctor who took my symptoms very seriously, and did an EKG. He didn’t have a lot to compare to, but he didn’t like what he saw, so he sent me directly for blood tests and arranged an appointment with a cardiologist. After further investigation, they found I had three blocked arteries, one of which was 100% blocked. To this day, I can’t be grateful enough to my primary care doctor for reacting so quickly.”

Available in six languages (Arabic, Chinese, English, Portuguese, Russian and Spanish), the international awareness campaign “Use Heart to Act Now on Angina” will be deployed on Facebook, Twitter, LinkedIn, and Instagram throughout April to September 2021.

Samuele Doratori, Head of Cardiovascular, Global Medical and Patient Affairs at Servier:
During the COVID-19 pandemic, an excess mortality resulting from cardiovascular diseases has been reported. As a health actor deeply involved in cardiovascular diseases, this crisis has reinforced our responsibility in providing relevant medical education for the management of these conditions, such as angina. Servier’s participation in this awareness initiative, conducted with WHF and the GHH, shows the Group’s strong mobilization to improve the lives of patients with chronic cardiovascular diseases.”

Fausto Pinto, World Heart Federation President: “Cardiovascular disease presents itself in many ways, including, angina. Symptoms of angina often go unheeded, can vary widely, and often manifest differently in men and women. WHF welcomes partnerships such as this one which are crucial for pooling knowledge and deploying experience to help beat cardiovascular disease – the world’s number one killer – claiming more than 18 million lives around the world each year.”

Neil Johnson, Director, Development & Strategy, Global Heart Hub: “Angina is a clear symptom of an underlying heart problem, and that’s why the Global Heart Hub wants to empower patients to Use Heart, connect with their health care provider and Act Now on Angina. We need to increase public awareness of angina, and encourage early detection and diagnosis, so that optimal management can be achieved and the impact on quality of life can be minimized.”

Leaphr-healthcare: The Definitive Virtual Event for Strategic HR Leaders in Healthcare

Leaphr-healthcare: The Definitive Virtual Event for Strategic HR Leaders in Healthcare

LEAP HR: Healthcare is your unique opportunity to plug into a community of strategic HR leaders from the most forward-thinking healthcare organizations across the globe, at a time when HR has never played a more vital role for employees and patients.

Step inside 40+ stories of how new, time-saving thinking is accelerating organizational agility and resilience across clinical and non-clinical healthcare workforces.

Take Part, & Leave Able to:

  • Find the urgent clinical talent your hospitals and medical centers need: Learn how Adventist HealthCare cut time to clear from six weeks to five days as new ICUs opened up
  • Rethink how to take care of your caregivers: Discover how Intermountain Healthcare rooted all its new people strategies in 2020 back to the insight it received from its caregivers
  • Eliminate differences for your diverse employees and patients: Find out how Spectrum Health designed a catalyst for future change and the creation of a new DE&I movement across the organization
  • Provide more opportunity to your employees on the lowest wage: Discover how Orlando Health has enabled team members on the lower end of the pay roll to be on a clear pathway to professional and personal growth
  • Fill vital talent supply gaps and build a more agile workforce: Hear how Memorial Sloan Kettering Cancer Center transformed the way it inspired its clinical workforce to fill critical open positions and keep up with organizational scale
  • Transform the healthcare leadership experience: Uncover how Moffit Cancer Center built an adaptable leadership experience program to enhance inclusion of ideas and diversity of approach, and build a safe space for its leaders
  • Breakaway from traditional HR models to transform the healthcare associate experience: Unpick the scalable, four-pronged approach behind how Mercy Health re-invented HR based on forward-thinking experience methodology

ABOUT US

LEAP HR forums provide industry-specific environments to challenge traditional thinking around how to build better companies. Our goal is to create a movement of bold, ambitious business leaders who want to change the way HR works, a mission which involves working with a remarkable group of HR leaders actively changing their companies from the inside.

Smiths Medical Partners With Parkview Health to Enhance Patient and Clinician Safety

Schneider Electric equips hospitals to effectively serve patients

Smiths Medical, a global medical device manufacturer, announced today that Parkview Health, based in Fort Wayne, Indiana., has integrated its PharmGuard® Infusion Management System with its electronic health record system to establish bi-directional interoperability across all hospital in its health system. Connected through their Epic electronic health record (EHR), this integration will enable smart pump programming and auto documentation to improve patient safety.

Smart pump programming and bi-directional interoperability simplifies nursing workflow and improves medication administration by allowing EHR to communicate directly with an infusion pump at the bedside. Clinician orders can be sent from the EHR to the pump, providing an extra level of safety for patients and care teams. This enables infusion program settings to be automatically checked against the EHR to ensure the correct medication, concentration, rate, dose and duration have been selected for the patient.

Interoperability can eliminate 75% of infusion-related medication errors.1 In addition, it can help to enhance clinical workflow and ensure timely and accurate documentation of all medication in the EHR.

“Safety is a top priority at Parkview Health and, by implementing this technology, we are pleased to add another layer of safety, accuracy and efficiency for our patients and care teams,” said Rebecca Mahuren, medication safety integration nurse, Parkview Regional Medical Center.

PharmGuard® Infusion Management System also reduces the number of steps a nurse must complete to program a pump, allowing them to spend more time with patients and less time with technology. This functionality helps nurses and other medical professionals to easily, quickly and accurately deliver the medication patients need.

“At Smiths Medical, we are dedicated to constantly improving both clinician and patient safety by connecting care, whether through our infusion pump systems, our hypodermics or our ventilators, in what continues to be an extremely demanding environment for all due to the global COVID-19 pandemic,” said Dr. Wilson P. Constantine, president of the Americas, Smiths Medical. “The successful EHR integration with Parkview demonstrates our ongoing commitment to enabling patient safety by reducing administration errors and delivering patient flow automation, which can free up clinicians to spend more time with their patients.”

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com.

About Smiths Group

A global technology company that has been operating for nearly 170 years, delivering products and services for the medical technology, security and defense, general industrial, energy and space & commercial aerospace markets worldwide. Smiths Group plc employs c. 23,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com.

Epic is a registered trademark of Epic Systems Corporation.

Biognosys Announces Strategic Agreement with Siemens Healthineers

Siemens Healthineers and IBM are working together to digitally network the healthcare system in Germany

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing, and commercialization capabilities.

Using Biognosys’ proprietary Hyper Reaction Monitoring (HRM™) mass spectrometry technology, thousands of proteins may be quantified simultaneously from a broad range of clinical sample types. HRM enables an unmatched depth of proteome coverage with reproducible and precise quantification to identify the most promising, actionable biomarkers to support clinical decision-making. This discovery proteomics solution can be applied with high throughput in large-scale studies involving thousands of samples.

The strategic agreement enables the discovery of novel biomarkers via the HRM technology followed by translation into validated biomarker assays for potential clinical applications. This may include clinical trial usage and In Vitro Diagnostics development programs.

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company’s proprietary solutions provide a multi-dimensional view of protein expression, function, and structure in all major biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at

 

Tomah Health special nonevent to support future healthcare staff

Tomah Health Community Foundation leaders are excited about a special nonevent designed to support future health care professionals.

The philanthropic organization sector of Tomah Health has held nonevent fundraising efforts that has raised more than $70,000 to support future health care providers over the last 13 years.

The foundation’s annual educational scholarship program funds three scholarships worth $1,500 each to students planning to have a career in healthcare.

When this first started our nonevent, we saw it as an opportunity to do something a little different, while continuing the work of the hospital foundation,” said organization president Pete Reichardt in a release. “With continued COVID safeguards, our nonevent guarantees that you don’t have to worry about showing up to an event and social distancing; all you have to do is consider a donation for a great cause that benefits our future health care.”

How To Choose The Right Hearing Aid

If you’ve long suffered from hearing loss, then hearing aids are a gift of technology. Now you can finally enjoy what everyone else you do – the gift of sound. With this comes so many other happy effects like listening to music, hearing voices, and even conversing. Life truly becomes better.

But, before these, you’ve first got to go through the process of selecting one. Especially if this is your very first time purchasing a hearing aid, even with the help of a specialist, the options can still be overwhelming. Hearing aids come in all forms, sizes, technology levels, and colors. So, you can’t just barge right into a shop that sells one and picks one at random. Think of this as an investment for a more comfortable life, so all the more that you’ve got to get this right.

To maximize its promising benefits, you’ve got to choose the right hearing aid for you. This article gives you tips on how to successfully achieve this.

  1. Bring A Friend or Family Member

Don’t shop alone. If possible, bring your spouse, a family member, or a friend. Especially when you’re still window shopping and you’re listening to the explanations of each seller as to the hearing aids they have, there must be others listening with you. They can lend you their ears – literally at that when you can’t use yours yet.

  1. Find A Good Provider

A hearing aid is an investment for your future, so you can live comfortably, and provide a solution to your hearing problems. You can’t expect to enjoy its maximum benefits when the quality of your hearing aid is inferior.

Most importantly, remember that throughout the course of using your hearing aid, you’ll be dealing regularly with your hearing aid provider. You wouldn’t want to keep visiting one that’s not friendly and is very difficult to deal with. Moreover, imagine the horror when your device is still under warranty and the shop where you bought it from has already closed!

With such an important device, there’s no room for you to downgrade your standards when looking for a good provider.

Plus, quality stores and providers may even give you ways to save, like a promo and discount code! If you don’t have to pay full price for your hearing aid, why miss out on that offer?

  1. Understand How Hearing Aids Work

Before you decide on using a hearing aid, it’s also very important that you first understand how it works. That way, you can be more convinced about the viability of getting one. Also, when you understand its parts and function, it’ll be easier for you to determine if there’s a problem or not.

For instance, there are some problems with a hearing aid that don’t necessarily need the help of a hearing specialist to fix. Especially for the minor issues, you can do these yourself. But you’ve also got to learn how to identify the bigger problems, that’s a call for you to check first an online hearing test and have it fixed or adjusted by the hearing instrument specialist.

All types of hearing aids work in the same way. It comes with a small microphone that works to collect sounds from the environment. This collected sound is then converted by an amplifier through the computer chip. That way, the signals are sent to your brain, for it to process them. That’s how you’re able to hear!

  1. Match the Features with Your Lifestyle

The advancements in technology have also brought new features in hearing aids today. Some of these features might come in handy for you, while others, you might find unnecessary. The key is to balance the features that you need most, depending on your lifestyle.

For instance, if you’re the type who loves to go out regularly, works in a noisy environment, and fancies loud music, then you’re better off using a hearing aid with the ability to reduce background noise, and enhances speech. If you’re usually just at home and the noise is minimal, then you don’t need to have this feature.

Apart from your lifestyle or hobbies, you should also match the features of your hearing aid with your work environment. Some work environments are noisier than others, so this is something you’ll want to factor in as well.

  1. Choose A Style You Like

Hearing aids don’t have to feel unfashionable. With the right style, some of these are even less visible than others! With so many options to choose from, you’re guaranteed to find one that truly meets your style preferences.

Here are some of the most common styles of hearing aid that are out in the market today:

  • Mini CIC or Completely-In-Canal (CIC)This type of hearing aid fits perfectly in the ear canal. This is best used for those who suffer from hearing loss which can be mild to moderate. The advantages of this hearing aid include being the least visible type, the smallest, and less wind noise to pick up.
  • In-The-Ear (ITE). Two ways to custom-made this type of hearing aid: one fills up the outer ear, and the other fills the lower part of the ear. This type is best used for patients who suffer from moderate to severe hearing loss. This kind of hearing aid may hold other features that aren’t available in the smaller models, and may also be easier to handle.
  • Receiver-In-The-Ear (RITE) or Receiver-In-Canal (RIC). These types are closely similar to the behind-the-ear (BTE) type of hearing aid that have a receiver or speaker sitting on the ear canal. However, rather than using tubing, there’s a tiny wire that connects the piece behind the ear to the receiver or the speaker.
  1. Get Tested

Buying a hearing aid isn’t a decision for you to make by yourself. Before you’ll purchase one, you’ll first need to get tested and assessed by a hearing specialist. That way, a diagnosis can be made whether or not you suffer from mild, moderate, or severe hearing loss. This is needed to narrow down the options of hearing aids you can choose from.

Conclusion

With these tips, now you’re ready to head out shopping for a hearing aid from a trusted specialist. This is a big milestone in your life, so it’s not something for you to take lightly. Take the time to go through the process carefully with ease and with thorough research. That way, you know for certain that your chosen hearing aid is the one that you truly need and prefer. Most importantly, you don’t have to go through this process alone. A hearing specialist will be necessary, not just to help assess your hearing needs and match them with the appropriate device, but also to fine-tune your hearing aid for your benefit and comfort.

American Cancer Society, Roundtrip Partner to Enable Transportation for Cancer Patients

Healthcare tech & ridesharing company Roundtrip has rolled out its platform with the American Cancer Society (ACS), specifically its ‘Road to Recovery’ program in order to enable cancer patients to connect to the treatment they need. The goal is to reduce the overall cancer mortality rate by 40% by 2035.

Together, Roundtrip and ACS will work to ease the stressful process of transportation coordination and allow patients to focus on what is most important – their care and recovery.

Roundtrip is a simple, comprehensive patient ride ordering software that connects patients with non-emergency medical transportation (NEMT). Roundtrip supports all levels of transport: volunteer drivers, rideshare, taxi, medical cars, wheelchair vans, stretcher vehicles, ALS/BLS ambulances, all payers, and all trips delivered when and where they are needed.

“The American Cancer Society is excited to leverage Roundtrip’s cutting-edge technology to assist patients in getting to life saving treatment,” says Chuck Westbrook, Senior Vice President of Cancer Control Programs and Services at the American Cancer Society. “We are confident that our patients and volunteers will benefit from this new transportation solution that helps patients overcome barriers to timely and high-quality care.”

Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology

Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology

Royal Philips, a global leader in health technology, and Ibex Medical Analytics, a pioneer in artificial intelligence (AI) based cancer diagnostics, announced a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide. The combination of Philips digital pathology solution (Philips IntelliSite Pathology Solution) and Ibex’s Galen™ AI-powered cancer diagnostics platform, currently in clinical use in Europe and the Middle East, empowers pathologists to generate objective, reproducible results, increase diagnostic confidence, and enable the productivity and efficiency improvements needed to cope with ever-increasing demand for pathology-based diagnostics.

Today’s announcement marks the latest extension to Philips’ AI-enabled Precision Diagnosis solutions portfolio, which leverages Philips and third-party AI solutions to deliver cutting-edge clinical decision support and optimized workflows that enable healthcare providers to deliver on the Quadruple Aim of better patient outcomes, improved patient and staff experiences, and lower cost of care.

The trend towards centralized pathology labs, the global shortage of trained pathologists, and increasing demands on histopathology posed by the growing number of cancer patients, leads pathology labs to actively seek efficiency-enhancing solutions that enable to maintain high accuracy levels. Digital pathology, enabled by solutions such as Philips IntelliSite Pathology Solution has already been shown to improve pathology lab productivity by 25% [2], while also allowing remote image reading by specialists and the immediate sharing of images with referring hospitals as part of comprehensive pathology reports. Ibex’s AI-powered Galen platform further streamlines workflow and improves accuracy via automated case prioritization, cancer heatmaps, grading and other productivity-enhancing tools.

“Building on our strong portfolio to support clinical decision-making in oncology, we bring together the power of imaging, pathology, genomics and longitudinal data with insights from artificial intelligence (AI) to help empower clinicians to deliver clear care pathways with predictable outcomes for every patient,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “By teaming with Ibex to incorporate their AI into our Digital Pathology Solutions, we’re further able to provide a continuous pathway, where critical patient data is made visible to both pathologists and oncologists to help improve the clinician experience and patient outcomes.”

“Pathology is transforming at an increasing pace and AI is one of the major drivers, supporting a more rapid and accurate cancer diagnosis,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics. “By joining forces with Philips, the leader in digital pathology deployments, we can offer new end-to-end solutions enabling pathologists to implement integrated, AI-powered workflows across a broader segment of the diagnostic pathway, improving the quality of patient care and strengthening the business case for digitization.”

Ibex’s Galen platform adds AI-powered cancer detection, case prioritization, grading and other productivity-enhancing insights. Users have reported significant improvements in diagnostic efficiency, with 27% reduction in time-to-diagnosis compared to conventional microscope viewing, 1- to 2-day reductions in total turnaround time, and 37% productivity gain [3]. In addition to cancer, the AI platform supports pathologists in the accurate grading, as well as detection and diagnosis of multiple clinical features, such as tumor size, perineural invasion, high-grade PIN (Prostatic Intraepithelial Neoplasia) and more. The accuracy level of Galen Prostate for cancer detection was the highest level reported in the field, with a sensitivity rate of 98.46%, specificity of 97.33% and an AUC of 0.991 [4]. When used as an automated ‘second read,’ the platform alerts pathologists when discrepancies between their diagnosis and the AI algorithm’s findings are detected, providing a safety net against error or misdiagnosis, previously reported as high as 12% [5], and increasing overall quality of care.

“We have been using Philips’ IntelliSite Pathology Solution together with Ibex’s Galen™ platform as part of our routine practice since 2020, and this ‘second read’ implementation has already helped us improve our diagnostic quality,” said Delphine Raoux, MD, pathologist and Head of Innovation Technologies at Medipath, the largest network of private pathology labs in France. “The work we presented recently showed that Ibex’s AI platform can further provide significant productivity gains when used during primary diagnosis and helps us reduce total turnaround time. This is an important step forward as we look for new technologies that can help meet an increasing demand for pathology services and could enable seamless remote reading of biopsies in times of COVID restrictions.”

Philips digital pathology solution is a comprehensive turnkey solution that helps to speed and simplify access to histopathology information across cancer care and beyond, supports full-scale digitization of histology in pathology labs and lab networks, and help increases workflow efficiency. At the heart is Philips IntelliSite Pathology Solution, which comprises an ultra-fast pathology slide scanner, an image management system and display [6], which includes advanced software tools to manage slide scanning, image storage, case review, and the sharing of patient information. By fully digitizing post-sample-preparation histopathology, it facilitates the streamlining of pathology workflows and enables the connectivity needed between multi-disciplinary teams and specialties when making complex cancer diagnosis and treatment decisions, from early detection and precision diagnosis through to precision treatment and predictable outcomes.

Through breakthrough innovations and partnerships, Philips integrates intelligence and automation into its Precision Diagnosis portfolio, including smart diagnostic systems, integrated workflow solutions that transform departmental operations, advanced informatics that provides diagnostic confidence, and care pathway solutions that allow medical professionals to tailor treatment to individual patients. By developing and integrating these AI-enabled applications, the company aims to enhance the ability to turn data into actionable insights and drive the right care in the right sequence at the right time.

Today’s partnership announcement with Ibex follows recent AI partnership announcements with DiA Imaging Analysis for AI-powered ultrasound applications, and AI software provider Lunit, incorporating its chest detection suite into Philips diagnostic X-ray suite. These partner solutions complement Philips own AI solutions in personal health, precision diagnosis and treatment, and connected care.

About Royal Philips

Royal Philips  is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries.

About Ibex Medical Analytics

Ibex uses AI to develop clinical-grade solutions that help pathologists detect and grade cancer in biopsies. The Galen™ platform is the first-ever AI-powered cancer diagnostics solution in routine clinical use in pathology and deployed worldwide, empowering pathologists to improve diagnostic accuracy, integrate comprehensive quality control and enable more efficient workflows. Ibex’s solutions are built on Deep Learning algorithms trained by a team of pathologists, data scientists and software engineers.

Translate »